Fecal microbiota transplantation refers to the practice of transplanting stool from a healthy donor into the gastrointestinal tract of the patient. This procedure restores the balance of bacteria in the digestive tract by replenishing the population of ‘good’ bacteria that is either suppressed by the overpopulation of ‘bad’ bacteria or has been killed. Prepared fecal microbiota transplantation is a thoroughly screened process. It is carried out in the lower gastrointestinal tract through colonoscopy or enema and in the upper gastrointestinal tract through the nasoduodenal or nasogastric tube. Currently, fecal microbiota transplantation is being studied for the treatment of Clostridium difficile infection but can be used for the treatment of gut dysbiosis after heavy treatment such as chemotherapy. Patietns with recurrent clostridium infections treated with fecal microbiota transplantation have shown high rates of success. A study has found that 90% recurrent C. difficile cases treated with fecal microbiota transplantation achieve clinical resolution. Thus, this has elevated fecal microbiota transplantation as an emerging treatment for a wide range of disorders, including fibromyalgia, Parkinson’s disease, myoclonus dystopia, chronic fatigue syndrome, multiple sclerosis, insulin resistance, obesity, metabolic syndrome, and autism.
The global Fecal Microbiota Transplantation market was valued at US$ 268 million in 2023 and is anticipated to reach US$ 386.6 million by 2030, witnessing a CAGR of 5.4% during the forecast period 2024-2030.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
This report aims to provide a comprehensive presentation of the global market for Fecal Microbiota Transplantation, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fecal Microbiota Transplantation.
Report Scope
The Fecal Microbiota Transplantation market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Fecal Microbiota Transplantation market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Fecal Microbiota Transplantation companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Âé¶¹Ô´´ Segmentation
By Company
Rebiotix
Finch Therapeutics
Seres Therapeutics
Crestovo
Segment by Type
Phase-I
Phase-2
Phase-3
Phase-4
Segment by Application
Clostridium Difficile Infections
Parkinson Disease
Obesity
Diabetes Mellitus
Autism
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Fecal Microbiota Transplantation companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Âé¶¹Ô´´ Analysis by Type
1.2.1 Global Fecal Microbiota Transplantation Âé¶¹Ô´´ Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Phase-I
1.2.3 Phase-2
1.2.4 Phase-3
1.2.5 Phase-4
1.3 Âé¶¹Ô´´ by Application
1.3.1 Global Fecal Microbiota Transplantation Âé¶¹Ô´´ Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Clostridium Difficile Infections
1.3.3 Parkinson Disease
1.3.4 Obesity
1.3.5 Diabetes Mellitus
1.3.6 Autism
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Fecal Microbiota Transplantation Âé¶¹Ô´´ Perspective (2019-2030)
2.2 Fecal Microbiota Transplantation Growth Trends by Region
2.2.1 Global Fecal Microbiota Transplantation Âé¶¹Ô´´ Size by Region: 2019 VS 2023 VS 2030
2.2.2 Fecal Microbiota Transplantation Historic Âé¶¹Ô´´ Size by Region (2019-2024)
2.2.3 Fecal Microbiota Transplantation Forecasted Âé¶¹Ô´´ Size by Region (2025-2030)
2.3 Fecal Microbiota Transplantation Âé¶¹Ô´´ Dynamics
2.3.1 Fecal Microbiota Transplantation Industry Trends
2.3.2 Fecal Microbiota Transplantation Âé¶¹Ô´´ Drivers
2.3.3 Fecal Microbiota Transplantation Âé¶¹Ô´´ Challenges
2.3.4 Fecal Microbiota Transplantation Âé¶¹Ô´´ Restraints
3 Competition Landscape by Key Players
3.1 Global Top Fecal Microbiota Transplantation Players by Revenue
3.1.1 Global Top Fecal Microbiota Transplantation Players by Revenue (2019-2024)
3.1.2 Global Fecal Microbiota Transplantation Revenue Âé¶¹Ô´´ Share by Players (2019-2024)
3.2 Global Fecal Microbiota Transplantation Âé¶¹Ô´´ Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Fecal Microbiota Transplantation Revenue
3.4 Global Fecal Microbiota Transplantation Âé¶¹Ô´´ Concentration Ratio
3.4.1 Global Fecal Microbiota Transplantation Âé¶¹Ô´´ Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Fecal Microbiota Transplantation Revenue in 2023
3.5 Fecal Microbiota Transplantation Key Players Head office and Area Served
3.6 Key Players Fecal Microbiota Transplantation Product Solution and Service
3.7 Date of Enter into Fecal Microbiota Transplantation Âé¶¹Ô´´
3.8 Mergers & Acquisitions, Expansion Plans
4 Fecal Microbiota Transplantation Breakdown Data by Type
4.1 Global Fecal Microbiota Transplantation Historic Âé¶¹Ô´´ Size by Type (2019-2024)
4.2 Global Fecal Microbiota Transplantation Forecasted Âé¶¹Ô´´ Size by Type (2025-2030)
5 Fecal Microbiota Transplantation Breakdown Data by Application
5.1 Global Fecal Microbiota Transplantation Historic Âé¶¹Ô´´ Size by Application (2019-2024)
5.2 Global Fecal Microbiota Transplantation Forecasted Âé¶¹Ô´´ Size by Application (2025-2030)
6 North America
6.1 North America Fecal Microbiota Transplantation Âé¶¹Ô´´ Size (2019-2030)
6.2 North America Fecal Microbiota Transplantation Âé¶¹Ô´´ Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Fecal Microbiota Transplantation Âé¶¹Ô´´ Size by Country (2019-2024)
6.4 North America Fecal Microbiota Transplantation Âé¶¹Ô´´ Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Fecal Microbiota Transplantation Âé¶¹Ô´´ Size (2019-2030)
7.2 Europe Fecal Microbiota Transplantation Âé¶¹Ô´´ Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Fecal Microbiota Transplantation Âé¶¹Ô´´ Size by Country (2019-2024)
7.4 Europe Fecal Microbiota Transplantation Âé¶¹Ô´´ Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Fecal Microbiota Transplantation Âé¶¹Ô´´ Size (2019-2030)
8.2 Asia-Pacific Fecal Microbiota Transplantation Âé¶¹Ô´´ Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Fecal Microbiota Transplantation Âé¶¹Ô´´ Size by Region (2019-2024)
8.4 Asia-Pacific Fecal Microbiota Transplantation Âé¶¹Ô´´ Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Fecal Microbiota Transplantation Âé¶¹Ô´´ Size (2019-2030)
9.2 Latin America Fecal Microbiota Transplantation Âé¶¹Ô´´ Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Fecal Microbiota Transplantation Âé¶¹Ô´´ Size by Country (2019-2024)
9.4 Latin America Fecal Microbiota Transplantation Âé¶¹Ô´´ Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Fecal Microbiota Transplantation Âé¶¹Ô´´ Size (2019-2030)
10.2 Middle East & Africa Fecal Microbiota Transplantation Âé¶¹Ô´´ Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Fecal Microbiota Transplantation Âé¶¹Ô´´ Size by Country (2019-2024)
10.4 Middle East & Africa Fecal Microbiota Transplantation Âé¶¹Ô´´ Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Rebiotix
11.1.1 Rebiotix Company Detail
11.1.2 Rebiotix Business Overview
11.1.3 Rebiotix Fecal Microbiota Transplantation Introduction
11.1.4 Rebiotix Revenue in Fecal Microbiota Transplantation Business (2019-2024)
11.1.5 Rebiotix Recent Development
11.2 Finch Therapeutics
11.2.1 Finch Therapeutics Company Detail
11.2.2 Finch Therapeutics Business Overview
11.2.3 Finch Therapeutics Fecal Microbiota Transplantation Introduction
11.2.4 Finch Therapeutics Revenue in Fecal Microbiota Transplantation Business (2019-2024)
11.2.5 Finch Therapeutics Recent Development
11.3 Seres Therapeutics
11.3.1 Seres Therapeutics Company Detail
11.3.2 Seres Therapeutics Business Overview
11.3.3 Seres Therapeutics Fecal Microbiota Transplantation Introduction
11.3.4 Seres Therapeutics Revenue in Fecal Microbiota Transplantation Business (2019-2024)
11.3.5 Seres Therapeutics Recent Development
11.4 Crestovo
11.4.1 Crestovo Company Detail
11.4.2 Crestovo Business Overview
11.4.3 Crestovo Fecal Microbiota Transplantation Introduction
11.4.4 Crestovo Revenue in Fecal Microbiota Transplantation Business (2019-2024)
11.4.5 Crestovo Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Rebiotix
Finch Therapeutics
Seres Therapeutics
Crestovo
Ìý
Ìý
*If Applicable.